D. Heath

发表

Biodegradable polymer/hydroxyapatite composites: surface analysis and initial attachment of human osteoblasts.

M. Textor, S. Rizzi, D. Heath, 2001, Journal of biomedical materials research.

Role of the cross-linking enzyme tissue transglutaminase in the biological recognition of synthetic biodegradable polymers.

D. Heath, A. Coombes, S. Downes, 2001, Journal of biomedical materials research.

The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis

M. Dimopoulos, D. Heath, P. Croucher, 2008, Leukemia.

Characterization of Tissue Transglutaminase in Human Osteoblast‐like Cells

D. Heath, S. Downes, M. Griffin, 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Involvement of tissue transglutaminase in the stabilisation of biomaterial/tissue interfaces important in medical devices.

D. Heath, Martin Griffin, Deborah J Heath, 2002, Biomaterials.

An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.

D. Heath, R. Murali, P. Croucher, 2007, Cancer research.

Inhibiting Dickkopf‐1 (Dkk1) Removes Suppression of Bone Formation and Prevents the Development of Osteolytic Bone Disease in Multiple Myeloma

J. Shaughnessy, D. Heath, J. Snowden, 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Serum concentrations of Dickkopf‐1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation

M. Dimopoulos, D. Heath, P. Croucher, 2006, International journal of cancer.

M. Dimopoulos, D. Heath, P. Croucher, 2008, Leukemia.

Bortezomib reduces serum dickkopf‐1 and receptor activator of nuclear factor‐κB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma

M. Dimopoulos, D. Heath, P. Croucher, 2006, British journal of haematology.

Bortezomib Reduces Serum Dickkopf-1 and RANKL Concentrations and Normalizes Indices of Bone Remodeling in Patients with Relapsed Multiple Myeloma.

M. Dimopoulos, D. Heath, P. Croucher, 2006 .

P3. A soluble activin type II receptor prevents the development of myeloma bone disease

D. Heath, P. Croucher, J. Seehra, 2008 .

Expression Profiling and Functional Analysis of Wnt Signaling Mechanisms in Mesenchymal Stem Cells

D. Heath, P. Genever, G. J. Spencer, 2004, Stem cells.

Inhibiting Dickkopf‐1 (Dkk1) Removes Suppression of Bone Formation and Prevents the Development of Osteolytic Bone Disease in Multiple Myeloma

J. Shaughnessy, D. Heath, J. Snowden, 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.